Q1 EPS Forecast for LENZ Therapeutics Lowered by Analyst

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at William Blair decreased their Q1 2025 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a note issued to investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn ($0.56) per share for the quarter, down from their previous estimate of ($0.48). The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. William Blair also issued estimates for LENZ Therapeutics' Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($2.97) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.67) EPS and Q4 2026 earnings at ($0.53) EPS.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

LENZ has been the topic of a number of other research reports. Citigroup boosted their price objective on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a research note on Thursday, March 20th. TD Cowen began coverage on shares of LENZ Therapeutics in a research report on Tuesday, March 18th. They set a "buy" rating and a $60.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $41.67.

Remove Ads

LENZ Therapeutics Stock Performance

Shares of NASDAQ:LENZ traded up $0.44 on Monday, hitting $26.53. The stock had a trading volume of 88,675 shares, compared to its average volume of 166,747. The firm's 50 day moving average price is $24.37 and its 200-day moving average price is $27.11. LENZ Therapeutics has a twelve month low of $14.42 and a twelve month high of $38.93. The company has a market capitalization of $730.72 million, a price-to-earnings ratio of -5.56 and a beta of 0.58.

Hedge Funds Weigh In On LENZ Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. GSA Capital Partners LLP acquired a new position in shares of LENZ Therapeutics in the 3rd quarter valued at $246,000. Charles Schwab Investment Management Inc. lifted its stake in LENZ Therapeutics by 197.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company's stock valued at $2,929,000 after buying an additional 81,901 shares during the period. The Manufacturers Life Insurance Company bought a new position in LENZ Therapeutics during the third quarter worth about $743,000. MetLife Investment Management LLC acquired a new position in shares of LENZ Therapeutics during the 3rd quarter worth about $182,000. Finally, BBR Partners LLC increased its stake in shares of LENZ Therapeutics by 100.0% in the 3rd quarter. BBR Partners LLC now owns 40,000 shares of the company's stock valued at $950,000 after acquiring an additional 20,000 shares during the last quarter. 54.32% of the stock is owned by institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.